AstraZeneca/Cellartis To Use Human Embryonic Stem Cells For Predictive Toxicology
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K. firm looks to increase safety, avoid expensive late-stage failures with preclinical screening on real human liver and heart muscle tissue.